Introduction
• Chronic myeloid leukaemia (CML) is a myeloproliferative disorder of blood stem cells, largely characterised by the presence of an aberrant gene 1 .
• Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib, are targeted therapies used in the treatment of CML 2 . Imatinib was the first TKI to be used and is still used extensively as a first-line therapy for CML 3 . Dasatinib and nilotinib are secondgeneration TKIs used as second-line treatments and, more recently, approved as first-line treatments for CML 3 .
• A systematic literature review (SLR) and network meta-analysis (NMA) were conducted in 2011 to compare imatinib, dasatinib and nilotinib as first-line treatments for CML 4 . Dasatinib and nilotinib were shown to be more efficacious than imatinib in the first-line treatment of CML 4 . No statistically significant difference in efficacy was shown between dasatinib and nilotinib 4 .
Objectives
To update the previous SLR and NMA 4 , assessing the relative efficacy of first-line treatments for CML and including newly published data with a follow-up period of up to 48 months.
Methods

Systematic literature review
• A comprehensive SLR was conducted to update a previous SLR conducted in March 2011 4 , identifying trials comparing first-line treatments in patients with CML (not previously treated with TKIs).
• Structured searches were conducted on 27 January 2014 in MEDLINE, Embase and the Cochrane Library, date restricted from March 2011 onwards. Hand searching of reference lists, conference abstracts and selected clinical trials registries was also conducted.
Indirect comparisons
• Studies included in the SLR were scrutinised with regard to study design, patient characteristics, interventions and other confounding factors to ensure they were sufficiently homogenous to allow for a robust meta-analysis.
• Indirect comparisons (ICs) were conducted to compare treatment efficacy using a fixed-effect Bayesian model implemented in WinBUGS software. A fixed-effect model was appropriate due to the small number of studies included.
• Outcomes of interest included cumulative complete cytogenic response (CCyR) by 6, 12 18 and 24 months, and major molecular response (MMR) by 12, 24, 36 and 48 months. Other outcomes, such as survival, other response outcomes and adverse events were also considered for analysis.
• Cumulative data was considered for the current analyses as this was the published and primary outcome measure in the DASISION trial.
Results
Systematic literature review
• In total, 74 relevant publications reporting on 30 studies were identified in the SLR (Figure 1 ). ). However, these studies reported CCyR or MMR at, rather than by, various time points and were therefore not eligible for inclusion. ‡ Based on 278 patients in the nilotinib 300 mg BD treatment arm and 282 patients in the imatinib 400 mg treatment arm.
Abbreviations: BD, twice daily; ECOG, Eastern Cooperative Oncology Group; OD, once daily; NR, not reported; RCT, randomised controlled trial.
Abbreviations: CCyR, complete cytogenic response; MMR, major molecular response; mths, months.
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Indirect comparisons
• Of the 74 publications identified in the SLR, 37 were excluded from the ICs due to study design, treatment, comparator, and / or patient characteristics. The remaining 37 publications reported on five unique RCTs eligible for inclusion in the ICs. However, two of the five studies (represented by two publications) reported CCyR and MMR at specific time points, but did not report these outcomes by specific time points. The three RCTs (35 publications) which reported CCyR and MMR by various time points (Table 1) were included in the evidence network for IC.
• There were insufficient comparable data available for other outcomes such as survival, other response outcomes and adverse events.
• Three studies which were also included in the original NMA 4 , were included in the evidence network for CCyR and MMR outcomes by follow-up time (Figure 2) . However, newly published data from these studies with longer follow-up was also included. In the previous NMA, imatinib 800 mg was included as a treatment comparator, however it is no longer considered a relevant treatment in first-line.
• The mean odds ratios (ORs) for CCyR associated with each treatment by each time point are summarised in Figure 3 .
• Nilotinib was significantly more efficacious than imatinib in terms of achieving CCyR by all time points. Compared with imatinib, dasatinib was significantly more efficacious in terms of achieving CCyR by 6 and 12 months.
• The mean ORs for MMR associated with each treatment by each time point are summarised in Figure 4 .
• Compared with imatinib, dasatinib and nilotinib were significantly more efficacious in terms of achieving MMR by all time points.
• There was no significant difference between dasatinib and nilotinib for either CCyR or MMR by any time point. 
Conclusions and limitations
• Analyses including all available RCTs suggest that the second-generation TKIs, dasatinib and nilotinib, are more efficacious than imatinib 400 mg and that there is no significant difference between dasatinib and nilotinib for the first-line treatment of newly diagnosed CML. This is consistent with the findings reported in current guidance for the first-line treatment of CML 19 and suggests that dasatinib and nilotinib should be the first-line treatments of choice from a clinical perspective.
• The results are also consistent with those reported in the previous SLR and NMA 4 and results reported by Signorovitch et al 2014 20 . Relative treatment effects were therefore maintained over a longer follow-up period.
• Limited data were available for use in the ICs. In all but one of the analyses, there was only one trial reporting data for each link of the evidence network ( Figure 2 ).
• As some patient characteristics were not available for all trials, there is a limitation on full comparison of patient populations studied.
• Using endpoints of CCyR and MMR by certain time points considers all patients who achieve CCyR or MMR even if the response is subsequently lost 20 . Further analysis is ongoing to present results at various time points. This will consider only patients who had achieved CCyR or MMR and maintained the response at specific time points.
